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Background-—Oxidative stress is implicated in the etiology of coronary heart disease (CHD). New measures to capture oxidative
stress are warranted. Fluorescent oxidation products (FlOPs) can be measured in plasma and have been shown to reﬂect levels of
oxidative stress and to predict risk of CHD in men over 6 years of follow-up. The objective of this study is to determine whether
measures of FlOPs are associated with risk of CHD in women over an extended follow-up period.
Methods and Results-—We measured FlOP by spectroﬂuorometer in a nested case–control study within the Nurses’ Health Study,
with baseline blood collection in 1990 and follow-up of 397 incident CHD cases through 2004 matched 1:2 with controls. Level of
FlOPs was independently associated with CHD. The relative risk across extreme quintiles was 1.64 (95% conﬁdence interval [CI],
1.06 to 2.53) when adjusted for lifestyle factors, lipids and C-reactive protein (P trend across quintiles=0.01). A slightly stronger
association was observed when analyses were restricted to women fasting >8 hours at blood draw (RR, 1.91; 95% CI, 1.16 to
3.15). In exploratory time to event analyses, high levels of FlOPs measured ≥5 years before the CHD event, but not closer to the
CHD event, were associated with the risk of CHD.
Conclusions-—Higher levels of FlOPs were associated with the risk of CHD in women. The association appeared strongest for long-
term prediction of CHD events. (J Am Heart Assoc. 2013;2:e000195 doi: 10.1161/JAHA.113.000195)
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A
ccumulation of cholesterol and chronic low-grade
inﬂammation in the arterial wall are the hallmarks of
atherosclerotic lesions. Reactive oxygen species released
from macrophages during the inﬂammatory process can
cause damage to cell structures and membranes, thereby
affecting lipids, protein, and DNA. Elevated levels of lipid
oxidation products have been associated with extensive
coronary artery calciﬁcation.
1 In particular, F2-isoprostanes,
which reﬂect the reaction of free radicals with arachidonic
acid, have been directly associated with coronary heart
disease (CHD) in several,
2,3 although not all,
4 studies. Yet
other measures of oxidative damage, such as measurement of
protein oxidation, have not been consistently linked with
CHD.
4
In previous work we reported a ﬂuorescent assay that
measures the Schiff base products from the interaction of
oxidation products with proteins, phospholipids, and nucleic
acids, producing chromophores with characteristic ﬂuores-
cence spectra.
5,6 Our ﬂuorescent method provides a nonspe-
ciﬁc but sensitive measure of oxidative products from lipids,
protein, carbohydrate, and DNA and is considered a global
measure of oxidation compared with speciﬁc oxidation
measurements such as measurement of F2-isoprostanes or
malondialdehyde.
6,7 We found that this global measure of
ﬂuorescent oxidation products was stable in plasma samples
collected and stored for 10 years,
5,8 that it was highly
correlated with cigarette smoking, and that it was a strong
and independent predictor of CHD in a prospective study of
US men and signiﬁcantly higher in patients with reduced renal
function in a case–control study.
9
Because women may have different underlying suscepti-
bility to oxidative stress in response to common environmen-
tal determinants and this may affect their risk of CHD in a
different manner than that observed in men,
1 we aimed to
address the association of plasma ﬂuorescent oxidation
products with CHD among women who participated in the
prospective Nurses’ Health Study. To extend our previous
analyses in men in the Health Professionals Follow-Up Study,
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ORIGINAL RESEARCHwe also explored the association of plasma ﬂuorescent
oxidation products measured across broader and more
variable wavelengths.
Methods
Design and Population
The Nurses’ Health Study enrolled 121 701 female nurses
aged 30 to 55 at baseline in 1976. Participants have since
been followed with biennial questionnaires to record newly
diagnosed illnesses and to update lifestyle information, as
published previously.
10 Between 1989 and 1990, a blood
sample was requested from all active participants in the
Nurses’ Health Study and collected from 32 826 women. A
nested case–control study of CHD was designed among
participants free of diagnosed cardiovascular disease or
cancer at blood draw by identifying all incident cases of CHD
between blood draw and June 2004 (n=474). Using risk-set
sampling,
11 controls were selected randomly and matched in a
1:2 ratio on age, smoking, and fasting status, among
participants who were free of cardiovascular disease at the
time CHD was diagnosed in the case. The diagnosis of CHD
included nonfatal myocardial infarction and fatal CHD. The
diagnosis of myocardial infarction was conﬁrmed on the basis
of the criteria of the World Health Organization (symptoms
plus either diagnostic electrocardiographic changes or ele-
vated levels of cardiac enzymes). Deaths were identiﬁed from
state vital records and the National Death Index or reported by
the participant’s next of kin or the postal system. Fatal CHD
was conﬁrmed by an examination of hospital or autopsy
records or by the listing of CHD as the cause of death on the
death certiﬁcate, if CHD was the underlying and most plausible
cause and if evidence of previous CHD was available.
We performed the current analysis in all participants with
complete information on 3 different ﬂuorescent measures and
all covariates. After excluding participants with any missing
information, we also excluded cases and controls who had no
matching control or case. Our ﬁnal data sets consisted of
1161 participants (397 case–control sets).
The study protocol was approved by the institutional
review board of the Brigham and Women’s Hospital and the
Human Subjects Committee Review Board of Harvard School
of Public Health.
Measurements
Demographic, anthropometric, and lifestyle data were derived
from questionnaires administered at blood draw in 1990.
Body mass index was calculated as weight in kilograms
divided by height in meters squared. Physical activity was
expressed in terms of metabolic-equivalent hours per week.
Participants reported whether a physician had ever diagnosed
them with diabetes or hypertension. The questionnaires and
the validity and reproducibility of measurements have been
described previously.
12
Blood samples were collected in tubes treated with
liquid sodium heparin. The tubes were then placed on ice
packs, stored in Styrofoam containers, returned to our
laboratory by overnight courier, centrifuged, and divided
into aliquots for storage in liquid-nitrogen freezers (130°C
or colder).
Measurement of ﬂuorescent oxidation products (FlOPs)
was performed with procedures previously described.
7 Brieﬂy,
plasma was extracted with ethanol–ether, and measurements
were assessed using a spectroﬂuorometer. FlOPs reﬂect lipid
oxidation products from reactions with protein, DNA, and
carbohydrate. The majority are measured in wavelengths with
excitation at 360 nm and emission at 420 nm (FlOP_360),
which we reported in previous studies to be stable, repro-
ducible, and predictive of CHD in men.
5,8 The ﬂuorescence
was determined as relative ﬂuorescence units per millimeter
of plasma. We also determined the relative ﬂuorescence
intensity at 2 alternative wavelengths. First, when lipid
hydroperoxides and secondary products, or aldehydes, ke-
tones, and dimeric compounds from oxidized linolenate, react
with DNA in the presence of metals and reducing agents, they
can generate products with excitation at 320 nm and
emission at 420 nm (FlOP_320).
6,13,14 Of note, malondialde-
hyde produced very little ﬂuorescent products with DNA in the
presence of metals and reducing agents.
6,13,14 Second,
products generated from malondialdehyde reacting with
proteins and phospholipids usually have a higher ﬂuorescent
spectra with excitation at 400 nm and emission at 475 nm
(FlOP_400).
6,15
Each batch in a laboratory analysis included the matched
case–control sets so that run-to-run variation in the analysis
would not add imprecision to the differences between cases
and controls. All laboratory personnel were blinded to the
case–control status. The within-run average coefﬁcient
variation (CVs) for all 3 measures were <13%.
We also measured FlOP_360, FlOP_320, and FlOP_400 in
40 Nurses’ Health Study participants who donated 2 blood
samples an average of 1.4 years apart (range, 0.8 to
2.2 years). After adjusting for fasting status, intraclass
correlations comparing repeated measurements were 0.44
for FlOP_360, 0.55 for FlOP_320, and 0.70 for FlOP_400;
within-person CVs were 39%, 52%, and 27% for FlOP_360,
FlOP_320, and FlOP_400, respectively.
Statistical Analysis
Baseline characteristics of participants who developed CHD
during follow-up and controls were assessed by means
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continuous variables and percentages of categorical variables.
Quintiles of FlOPs were calculated using the distributions in
the controls. We examined the distribution of lifestyle
characteristics and cardiovascular biomarkers across quin-
tiles of FlOPs in controls. Relative risks (RRs) and 95%
conﬁdence intervals (CIs) for CHD risk were estimated by
incidence rate ratios from unconditional logistic regression,
with adjustment for the matching factors (age2 years;
month of blood draw [quintiles]; fasting status [yes/no]; and
smoking status [never, past <15 cigarettes/day, past 15+
cigarettes/day, current <15 cigarettes/day, current 15+
cigarettes/day]). The results were similar to conditional
logistic regression models but allowed for maximum statisti-
cal power in stratiﬁed analyses without losing unmatched
participants in strata.
11 In multivariable analyses we adjusted
for the matching factors as well as alcohol intake, body mass
index, physical activity, family history of myocardial infarction,
and self-reported history of hypertension, diabetes, and
hypercholesterolemia. Additional analyses further adjusted
for low-density lipoprotein and high-density lipoprotein cho-
lesterol, triglycerides, and C-reactive protein. Tests for linear
trend were conducted by analyzing the median value of the
FlOP quintile as a continuous variable. In light of earlier results
suggesting the importance of considering fasting status,
5,7 we
also conducted an analysis restricted to women who had
fasted 8 hours or more before blood draw. We conducted
analyses of FlOP1, FlOP2, and FlOP3 separately and con-
ducted an explorative factor analysis to create a composite
score of the 3 FlOP measures. We also related this common
factor to risk of CHD. Finally, we examined whether the
association between the FlOP measures and CHD differed by
length of time between blood draw and the CHD event, by
hypertension, or by smoking status. For the interaction
analyses, we modeled the log-transformed FlOPs as linear
variables (standardized each FlOP by z scores). All analyses
were performed using SAS 9 (SAS Institute Inc, Cary, NC).
Results
As expected, the cases had higher plasma levels of triglyce-
rides, low-density lipoprotein cholesterol, and C-reactive
protein compared with the controls. Median levels of the 3
FlOP measures were also higher in cases compared with
controls (Table 1). FlOP_360 and FlOP_400 were highly
correlated (Spearman age-adjusted r=0.8, P<0.001) and
FlOP_360 and FlOP_320 less so (r=0.4). FlOP_320 and
FlOP_400 were only modestly correlated (r=0.2), and no
strong correlations with plasma lipids or C-reactive protein
were observed (data not shown).
FlOP_360 and FlOP_400 were strongly associated
with smoking status, with much higher levels observed
among current smokers. Thus, we chose to standardize the
characteristics presented according to quintiles of FlOPs
by smoking status (Table 2). High levels of the FlOP
measures were also correlated with consuming more alcohol,
having hypertension, and having diagnosed hypercholester-
olemia. Women with the highest FlOP concentrations
were also less likely to self-report a history of diabetes
Table 1. Baseline Characteristics of Women in Whom
Coronary Heart Disease Developed During Follow-up and
Matched Controls in the NHS*
Variable Cases (n=397) Controls (n=779)
Age, y 60.1 (6.5) 59.8 (6.6)
BMI, kg/m
2 26.6 (5.4) 25.1 (4.3)
Current smoker, % 24 24
Fasting >8 h, % 75 73
Alcohol intake (g/day),
median (IQR)
0.9 (0.0, 5.6) 1.8 (0.0, 8.6)
Physical activity,
METh/week
18.2 (22.4) 18.8 (19.7)
White ethnicity, % 99 100
Postmenopausal, % 85 84
Family history of MI, % 22 13
Diabetes,
† % 15 5.4
Hypercholesterolemia,
† %5 3 4 2
Hypertension,
† %5 1 2 9
CVD biomarkers
Total cholesterol,
mmol/L
6.00 (1.04) 5.87 (1.05)
LDL-C, mmol/L 3.71 (0.95) 3.51 (0.97)
HDL-C, mmol/L 1.35 (0.39) 1.54 (0.43)
Triglycerides
(mmol/L),
median (IQR)
1.40 (0.99, 1.99) 1.19 (0.86, 1.65)
CRP (g/L),
median (IQR)
0.26 (0.12, 0.55) 0.19 (0.08, 0.38)
FlOP_360,
median (IQR)
229 (177, 307) 216 (174, 277)
FlOP_320,
median (IQR)
412 (303, 712) 380 (297, 594)
FlOP_400,
median (IQR)
64.6 (50.1, 89.8) 61.0 (48.4, 83.6)
BMI indicates body mass index; CRP, C-reactive protein; CVD, cardiovascular disease;
FlOP, ﬂuorescent oxidation product; HDL-C, high-density lipoprotein cholesterol; IQR,
interquartile range; LDL-C, low-density lipoprotein cholesterol; METh/week, metabolic
equivalent hours per week; MI, myocardial infarction; NHS, Nurses’ Health Study.
*Data are presented as means (SDs) unless otherwise indicated. Matching criteria were
age, smoking, date of blood sampling, and fasting status. FlOPs are presented as relative
ﬂuorescent intensity/mL of plasma. To convert cholesterol concentrations from mmol/L
to mg/dL, divide by 0.0259. To convert triglycerides from mmol/L to mg/dL, divide by
0.0113.
†Self-reported diagnosis before blood draw.
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Hand had a slightly lower body mass index. There were no
strong associations between FlOP measures and lipid
markers.
High FlOP_360 level was associated with risk of CHD. This
association was especially apparent on subsequent adjust-
ment for lifestyle and cardiovascular disease biomarkers
(Table 3). The RR in the top quintile was 1.64 (95% CI, 1.06 to
2.53) compared with the lowest quintile. The participants with
the highest FlOP_320 levels had a statistically nonsigniﬁcant
elevated risk of CHD. Only in the multivariable model
including adjustment for biomarkers was the test for trend
signiﬁcant (Ptrend=0.03). FlOP_400 was associated with risk in
a manner very similar to that observed for FlOP_360 (RR for
the comparison of the top versus bottom quintile was 1.75;
95% CI, 1.09 to 2.80). Associations for both FlOP_360 and
FlOP_400 were slightly stronger when restricted to the
women who had fasted >8 hours before venipuncture. We
created a composite score for the FlOP measures by factor
analysis. It was determined that FlOP1 and FlOP3 contributed
to most of the variation in this common factor, whereas FlOP2
did not load very high. The composite score was directly
associated with risk of CHD in logistic regression models, and
the fully adjusted RR for the top quintile was 1.81 (95% CI,
1.09 to 3.01; Ptrend=0.02) among the fasting women (data not
shown).
Although we did not detect any statistically signiﬁcant
effect modiﬁcation by self-reported physician-diagnosed
hypertension, hypercholesterolemia, or smoking status (all P
for statistical interaction>0.3), associations with CHD were
strongest among participants without hypertension and
without hypercholesterolemia. Associations for FlOP_320
and FlOP_400 were strongest in past and current cigarette
smokers and strongest among the current smokers (RR per
each unit increase in z score for log-transformed FlOP_320=
1.44, 95% CI, 1.06 to 1.95, and for FlOP_400=1.20, 95% CI,
0.83 to 1.75).
We further explored the potential role of the FlOP
measurements as acute or long-term markers of risk for
CHD by stratifying our analyses on time to event from blood
draw. None of the 3 FlOP measurements were signiﬁcantly
associated with the short-term risk of CHD, whereas an
elevated risk of CHD was observed when the CHD event
occurred ≥5 years after the blood draw (Figure). The RR of
CHD per each unit increase in z score for FlOP_360 was 0.86
(0.67 to 1.11) the ﬁrst 5 years of follow-up and 1.23 (1.04 to
1.46) for events occurring ≥6 years after baseline blood
collection. Similar point estimates were observed for
FlOP_320 and FlOP_400. We observed that the associations
in general were stronger as the duration of follow-up
increased.
Table 2. Characteristics According to Quintiles of the 3 FlOP Measurements in Controls From the Nurses’ Health Study*
Characteristic
FlOP_360 FlOP_320 FlOP_400
Q1 Q3 Q5 Q1 Q3 Q5 Q1 Q3 Q5
Age, y 59.0 (7.5) 59.1 (6.7) 60.5 (6.5) 58.9 (6.9) 60.2 (6.3) 60.4 (6.2) 58.5 (6.7) 59.5 (6.3) 60.7 (6.5)
BMI, kg/m
2 25.8 (4.5) 25.4 (4.6) 24.7 (3.9) 25.1 (3.9) 25.3 (4.5) 24.7 (3.9) 26.2 (4.7) 25.0 (4.2) 25.0 (4.1)
Current smoker, % 3 22 33 4 28 24 3 19 58
Alcohol intake,
g/day
3.3 (6.8) 5.3 (8.1) 6.5 (10.5) 5.6 (11.2) 6.7 (10.6) 5.3 (10.1) 3.9 (7.6) 6.0 (9.6) 7.2 (11.4)
Diabetes,
† % 674595764
High cholesterol,
† % 3 54 64 73 24 54 14 33 94 8
Hypertension,
† % 2 42 73 81 73 53 52 72 24 4
CVD biomarkers
Total cholesterol,
mmol/L
5.3 (1.3) 6.0 (1.1) 5.9 (1.2) 5.6 (1.1) 5.9 (1.1) 5.8 (1.0) 5.6 (0.9) 5.8 (1.0) 5.9 (1.4)
LDL-C, mmol/L 3.1 (1.0) 3.6 (1.1) 3.6 (1.1) 3.3 (0.9) 3.5 (1.0) 3.4 (0.9) 3.3 (0.8) 3.4 (0.9) 3.5 (1.2)
HDL-C, mmol/L 1.4 (0.4) 1.5 (0.5) 1.6 (0.5) 1.5 (0.4) 1.5 (0.4) 1.6 (0.4) 1.5 (0.4) 1.6 (0.5) 1.6 (0.5)
Triglycerides,
mmol/L
1.3 (0.6) 1.4 (0.7) 1.3 (0.8) 1.2 (0.5) 1.4 (0.8) 1.3 (0.8) 1.4 (0.6) 1.4 (0.9) 1.3 (0.7)
CRP, g/L 0.3 (0.4) 0.3 (0.4) 0.4 (0.5) 0.3 (0.5) 0.3 (0.3) 0.4 (0.5) 0.4 (0.5) 0.4 (0.6) 0.4 (0.4)
Quintiles 1 (Q1), 3 (Q3), and 5 (Q5) among the controls. BMI indicates body mass index; CRP, C-reactive protein; CVD, cardiovascular disease; FlOP, ﬂuorescent oxidation product; HDL-C,
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
*Values are means (SDs) or percentages and are standardized to the distribution of smoking status.
†Self-reported diagnosis before blood draw.
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HDiscussion
In this prospective study of generally healthy middle-aged
women, a global measure of oxidative stress, as assessed by
our ﬂuorescent oxidation product assay, was associated with
the risk of future CHD. Our results indicated that measures
obtained at wavelengths between 360 and 475 nm were most
correlated and generally showed the strongest association. In
exploratory analyses we found evidence to suggest that FlOP
measurements were better CHD predictors if CHD events
occurred 5 years after blood draw.
Other studies have reported associations between differ-
ent measures of oxidative stress and cardiovascular disease.
Compared with controls, measures of malondialdehyde, a
breakdown product from lipid peroxidation, have been found
to be elevated in stroke patients,
16 and 8-hydroxy-2′-deoxy-
guanosine levels, a measure of DNA damage, signiﬁcantly
predict cardiac events among patients with chronic heart
failure.
17 F2-isoprostanes, another marker speciﬁc to the
oxidation of lipids, has been associated with early stages of
coronary artery calciﬁcation in young healthy adults,
1 and
higher levels have also been observed in patients with
ischemic events compared with controls.
2,3 Although a link
between oxidative stress and atherosclerosis has been
suggested from these studies, most of them have been small
and constrained to elderly populations and patients with
advanced atheroslcerosis
18 or have been cross-sectional.
2,3,16
Because both in vitro and animal models demonstrate that
oxidative stress plays an important role in the initiation and
progression of atherosclerotic diseases,
19,20 it is important to
evaluate the role of these oxidative markers as predictors of
plaque formation in a prospective setting of generally healthy
participants. In our study, we were able to perform exploratory
analyses stratiﬁed by years of follow-up. We found that FlOP
levels were more strongly associated with the long-term risk
of CHD but not with CHD within the ﬁrst 5 years after FlOP
measurement. A study conducted in CARDIA indicated that
oxidative stress measured by F2-isoprostanes, a marker of
lipid oxidation, played a role in the early stages of athero-
sclerosis.
1 It is unlikely that participants in our older study
population (age range of 43 to 70 years at the time of blood
draw) are in the early stages of atherosclerosis; however, our
Table 3. Multivariable-adjusted IRR and 95% Conﬁdence Intervals of CHD According to Quintiles of the 3 FlOP Measurements in
the NHS
Q1 Q2 Q3 Q4 Q5
P Value for
Trend
FlOP_360
Median (range) 149 (<166) 182 (166 to 198) 217 (199 to 236) 265 (237 to 298) 392 (>298)
Unadjusted 1 (ref) 1.11 (0.75 to 1.64) 0.86 (0.57 to 1.31) 1.11 (0.73 to 1.70) 1.52 (1.02 to 2.25) 0.01
Multivariable adjusted — 1.17 (0.77 to 1.78) 0.93 (0.60 to 1.45) 1.19 (0.76 to 1.87) 1.53 (1.01 to 2.34) 0.03
+ Biomarkers — 1.13 (0.74 to 1.73) 0.94 (0.60 to 1.48) 1.22 (0.77 to 1.94) 1.64 (1.06 to 2.53) 0.01
+ Biomarkers, fasting only — 1.18 (0.73 to 1.90) 1.00 (0.59 to 1.68) 1.31 (0.76 to 2.24) 1.91 (1.16 to 3.15) 0.01
FlOP_320
Median (range) 246 (<284) 312 (284 to 345) 381 (345 to 424) 505 (425 to 720) 3531 (>720)
Unadjusted 1 (ref) 0.80 (0.54 to 1.21) 0.97 (0.65 to 1.46) 1.06 (0.71 to 1.59) 1.28 (0.87 to 1.80) 0.05
Multivariable adjusted — 0.80 (0.52 to 1.23) 0.83 (0.54 to 1.27) 0.99 (0.64 to 1.52) 1.20 (0.80 to 1.81) 0.07
+ Biomarkers — 0.75 (0.48 to 1.16) 0.82 (0.53 to 1.27) 0.96 (0.62 to 1.49) 1.25 (0.82 to 1.89) 0.03
+ Biomarkers, fasting only — 0.78 (0.48 to 1.27) 1.01 (0.61 to 1.67) 1.15 (0.69 to 1.92) 1.34 (0.83 to 2.17) 0.10
FlOP_400
Median (range) 41 (<46) 51 (46 to 56) 61 (56 to 69) 78 (69 to 89) 113 (>89)
Unadjusted 1 (ref) 1.11 (0.74 to 1.66) 1.32 (0.88 to 1.97) 1.10 (0.72 to 1.68) 1.64 (1.07 to 2.53) 0.03
Multivariable adjusted — 1.27 (0.83 to 1.95) 1.52 (1.00 to 2.33) 1.16 (0.74 to 1.83) 1.66 (1.05 to 2.62) 0.07
+ Biomarkers — 1.31 (0.85 to 2.02) 1.55 (1.01 to 2.40) 1.15 (0.72 to 1.83) 1.75 (1.09 to 2.80) 0.05
+ Biomarkers, fasting only — 1.51 (0.92 to 2.47) 1.65 (1.00 to 2.72) 1.46 (0.85 to 2.50) 1.93 (1.12 to 3.35) 0.06
Medians for FlOPs are presented as relative ﬂuorescent intensity per milliliter of plasma. Unadjusted model includes matching factors only (age, smoking, time of blood draw, and fasting
status). Multivariable model includes matching factors and alcohol, physical activity, BMI, family history of MI, history of hypertension, diabetes, hypercholesterolemia. Model with
biomarkers additionally adjusted for continuous measures of LDL, HDL, TG, and CRP. Fasting women only, n=889 (306 cases). Fasting >8 hours before blood draw. P for trend is test of
linear trend across quintiles using medians as continuous variable. BMI indicates body mass index; CHD, coronary heart disease; CRP, C-reactive protein; FlOP, ﬂuorescent oxidation
product; HDL, high-density lipoprotein; IRR, incidence rate ratio; LDL, low-density lipoprotein; MI, myocardial infarction; NHS, Nurses’ Health Study; TG, triglycerides.
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Hpreliminary ﬁndings may suggest that FlOP may represent a
long-term marker of elevated risk. More studies on FlOP in
both early-stage atherosclerosis and with long follow-up are
needed to examine this in greater detail. One other prospec-
tive study conducted in a generally healthy population had a
median follow-up of only 5.6 years and did not ﬁnd an
association between F2-isoprotanes and risk of CHD.
4 Our
ﬁndings suggest that the follow-up time may not have been
sufﬁcient or that the null association for the F2-isoprostane
marker could also be related to this marker, only capturing
the lipid portion of oxidative stress. Nevertheless, our ﬁndings
suggest that FlOPs might be useful as a monitoring biomarker
for early prevention.
We also evaluated the association of the FlOP measures
with CHD in separate subgroups. Although these analyses
were limited by smaller number of cases within strata, the
associations for FlOP_320 were stronger in some subgroups
such as among current smokers and participants without
hypertension or hypercholesterolemia. The differential pat-
terns of FlOPs with CHD among different subgroups merit
further investigation. It is likely that oxidative stress is a
stronger risk factor in some compared with other subgroups,
and this might reﬂect underlying oxidative damage.
We have previously reported on the prospective associa-
tion between our global oxidative stress measure and CHD in
the male Health Professionals Follow-Up Study. In comparison
with other measurements that only captured 1 aspect of
oxidation (lipid peroxidation, DNA damage, or protein oxida-
tion), a global measure may be a better marker of systematic
oxidation. In the present study, we also measured FlOPs at 2
alternative wavelengths. Although FlOP_320 was not strongly
associated with risk of CHD in the main analyses, the strongly
correlated measures of FlOP_360 and FlOP_400 showed
similar associations. A derived composite score of the
measures had a slightly stronger association with risk of
CHD across quintiles. It is possible that combining the 3 FlOP
measures helped to reduce measurement error. The factor
analysis also highlighted that FlOP_320 did not contribute
much to explaining the variation in the common score. Other
reasons for the lack of relationship of FlOP_320 with risk of
CHD include the higher within-person variation for this
measure compared with the others. Previously, we found
that the relative risk associated with high levels of FlOP_360
was greatest when restricted only to the men who had
provided fasting samples. In the present study among female
nurses, the analyses were matched on fasting status, and the
associations were modestly stronger when restricted to
fasting women. Thus, postprandial oxidation may modestly
affect the overall FlOP measurement, and fasting samples
might be preferable if used as a predictive marker reﬂecting
systemic exposure to oxidation.
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Figure. Multivariable-adjusted RRs for CHD per 1 z-score increase in
each log-transformed FlOP measure (relative ﬂuorescent intensity/ml)
in the Nurses’ Health Study in strata of length of follow-up (≤5 yr [112
cases occurred] and >5 yr [285 cases occurred]). RRs are incidence
rate ratios (IRR) obtained from logistic regression models adjusted for
matching factors (age, smoking, time of blood draw, and fasting
status) and alcohol, physical activity, BMI, family history of MI, history
of hypertension, diabetes, hypercholesterolemia, LDL, HDL, TG, and
CRP. BMI indicates body mass index; CHD, coronary heart disease;
CRP, C-reactive protein; FlOP, ﬂuorescent oxidation product; HDL,
high-density lipoprotein; LDL, low-density lipoprotein; RR, relative risk;
TG, triglycerides. Error bars indicate 95% conﬁdence interval.
DOI: 10.1161/JAHA.113.000195 Journal of the American Heart Association 6
FlOPs and Risk of CHD Jensen et al
O
R
I
G
I
N
A
L
R
E
S
E
A
R
C
HThis study had several limitations. First, we only had a
single blood sample at baseline. Although we did not observe
large changes, especially in FlOP_400 (intraclass correla-
tion=0.70), over an average of 1.4 years, we do not know if a
single measurement accurately reﬂected average levels over a
prolonged period. Second, we adjusted for a range of
cardiovascular risk factors, but because of the observational
study design, we cannot exclude the possibility of residual
confounding.
Third, although FlOP measurements have been repeatedly
shown to predict risk of CHD in both men
5 and women, the
detailed components of the oxidation products in FlOP
measurements need to be determined in the future. Fourth,
the majority of our participants were white, and the predictive
ability among other ethnic groups will need to be conﬁrmed in
the future.
In summary, this prospective study extended the previ-
ously observed association between FlOP measurements
obtained at wavelengths between 360 and 475 nm and risk of
CHD to a population of generally healthy women. Our results
suggest that the FlOP measurement may be a long-term
marker of CHD risk, a ﬁnding that warrants further investi-
gation to advance our understanding of this measure of
oxidative stress in relation to atherosclerosis progression.
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